Recent News

• 03.24.2026 - LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
• 03.17.2026 - LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
• 03.10.2026 - LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
• 02.23.2026 - LENZ Therapeutics to Present at Upcoming Investor Conferences
• 01.14.2026 - LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
• 01.07.2026 - LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
• 01.05.2026 - LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
• 12.01.2025 - LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
• 11.25.2025 - LENZ Therapeutics to Present at Upcoming Investor Conferences

Recent Filings

• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.05.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.21.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.07.2026 - 8-K Current report
• 01.07.2026 - EX-99.1 EX-99.1
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.12.2025 - 8-K Current report